Search research articles
Contact Us
Filters
Showing results (1-10 of 54) with videos related to
Page
of 6
Sort By:
Epigenomics
|
November 30, 2011
Targeting histone deacetylases: development of vorinostat for the treatment of cancer
Victoria M Richon
Nature Biotechnology
|
June 10, 2008
A new path to the cancer epigenome
Victoria M Richon
Hematology. American Society of Hematology. Education Program
|
December 10, 2013
Drug discovery in rare indications: opportunities and challenges
Victoria M Richon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2002
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment
Victoria M Richon, James P O'Brien
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2007
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications
Valeria R Fantin, Victoria M Richon
Current Opinion in Pharmacology
|
August 7, 2003
Histone deacetylases
Paul A Marks, Thomas Miller, Victoria M Richon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2015
CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy
Wm Kevin Kelly, Paul Marks, Victoria M Richon
Current Opinion in Investigational Drugs (London, England : 2000)
|
February 7, 2004
HDAC inhibitors for the treatment of cancer
J Paul Secrist, Xianbo Zhou, Victoria M Richon
Cancer Letters
|
February 3, 2009
Development of vorinostat: current applications and future perspectives for cancer therapy
Victoria M Richon, Jose Garcia-Vargas, James S Hardwick
Nature Reviews. Drug Discovery
|
September 2, 2009
Protein methyltransferases as a target class for drug discovery
Robert A Copeland, Michael E Solomon, Victoria M Richon
Page
of 6
Search research articles
Search
Showing results (1-10 of 54) with videos related to
Sort By:
Page
of 6
Epigenomics
|
November 30, 2011
Targeting histone deacetylases: development of vorinostat for the treatment of cancer
Victoria M Richon
Nature Biotechnology
|
June 10, 2008
A new path to the cancer epigenome
Victoria M Richon
Hematology. American Society of Hematology. Education Program
|
December 10, 2013
Drug discovery in rare indications: opportunities and challenges
Victoria M Richon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2002
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment
Victoria M Richon, James P O'Brien
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2007
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications
Valeria R Fantin, Victoria M Richon
Current Opinion in Pharmacology
|
August 7, 2003
Histone deacetylases
Paul A Marks, Thomas Miller, Victoria M Richon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2015
CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy
Wm Kevin Kelly, Paul Marks, Victoria M Richon
Current Opinion in Investigational Drugs (London, England : 2000)
|
February 7, 2004
HDAC inhibitors for the treatment of cancer
J Paul Secrist, Xianbo Zhou, Victoria M Richon
Cancer Letters
|
February 3, 2009
Development of vorinostat: current applications and future perspectives for cancer therapy
Victoria M Richon, Jose Garcia-Vargas, James S Hardwick
Nature Reviews. Drug Discovery
|
September 2, 2009
Protein methyltransferases as a target class for drug discovery
Robert A Copeland, Michael E Solomon, Victoria M Richon
Page
of 6